Abstract
Background Hypertension is a major risk factor for cardiovascular disease. Although it is well established that physical activity is cardioprotective, it is less clear how cardiovascular stress-related properties (i.e. intensity and bout length) determine future cardiovascular risk in adults with hypertension.
Objectives We examined the dose-response associations of moderate and vigorous physical activity bouts of variable length with major adverse cardiovascular events (MACE) and its sub-types (stroke, myocardial infarction, heart failure) in adults with hypertension.
Methods Participants of the UK Biobank wearables sub-study with a clinical diagnosis of hypertension. Short bouts of moderate activity were classified as lasting up to 3 minutes and for vigorous activity up to 1 minute. Long bouts of moderate activity were classified as lasting >5 minutes, and for vigorous activity >2 minutes. In sensitivity analyses we also tested alternative vigorous intensity bout length definitions for short (up to 2 minutes) and long (> 3, >4, and >5 minutes).
Results Among 36,957 participants (62.1 (SD= 7.7) years; 58.4% female) with an average follow up of 7.9 (1.1) years, 1,374 MACE, 394 stroke, 623 myocardial infarction, and 357 heart failure events occurred. Moderate intensity was associated with lower risk of MACE and its individual sub-types for both short (<3 mins) and long (>5 mins) bout lengths with a stronger dose-response magnitude for longer bouts. We observed a consistent inverse dose response association for vigorous intensity accrued through short bouts (<1 min) and overall MACE, stroke, myocardial infarction, and heart failure risk. The median duration of 3.5 minutes/day corresponded to a hazard ratio (HR) ranging between 0.57 [0.39, 0.83] for heart failure to 0.66 [0.46, 0.96] for stroke.
In contrast, vigorous intensity activity accrued through longer bouts showed a steep linear dose-response association for higher stroke risk. The median (6.0 minutes/day) and maximum (9.0 minutes/day) of activity accrued through vigorous bouts lasting >2 mins were associated with stroke HRs of 2.06 [1.38, 3.07] and 2.80 [1.72, 4.56], respectively. Additional analyses in 1 extra minute bout length increments revealed that the higher the “long bout” threshold the steeper the stroke risk, e.g the median of bouts lasting >5 mins (6.4 minutes/day) was associated with a HR of 2.69 [1.72, 4.21].
Conclusion For adults with hypertension, moderate intensity and short bouts of vigorous intensity were beneficially associated with lower MACE, stroke, myocardial infarction, and heart failure risk. Vigorous intensity accumulated in long bouts showed a steep deleterious dose-response with stroke risk, and were not associated with lower overall MACE, myocardial infarction, or heart failure. Our results highlight the importance of bout length for vigorous intensity as a determining factor for cardiovascular health in adults with hypertension.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is funded by an Australian National Health and Medical Research Council (NHMRC) Investigator Grant (APP 1194510) and a National Heart Foundation Grant (APP 107158). The funders had no specific role in any of the following study aspects: the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
